Mitsubishi Tanabe Pharma announces use of RADICUT for treating ALS patients in Japan
Mitsubishi Tanabe Pharma Corporation issued a press release on June 26 announcing that it had received approval to use RADICUT (Edaravone) in treating patients with ALS in Japan. The announcement comes after a series of clinical trials in Japan were said to demonstrate that patients receiving the drug showed less functional loss than patients receiving a placebo. We look forward to seeing the data supporting approval in Japan. Read press release here.